09/444, >84

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins									
Term:	knob and L4									
Display:	Documents in Display Format:	Starting with Number 1								
Generate: ○ Hit List ● Hit Count ○ Side by Side ○ Image										
Search Clear Interrupt										
Search History										

DATE: Monday, August 23, 2004 Printable Copy Create Case

Set Name side by side	Query	<u>Hit</u> <u>Count</u>	Set Name result set
DB=PC	GPB,USPT; PLUR=YES; OP=AND		
<u>L5</u>	knob and L4	5	<u>L5</u>
<u>L4</u>	12 and L3	5	<u>L4</u>
<u>L3</u>	adenovir\$ near3 (12 or 16 or 28 or 40)	1361	<u>L3</u>
<u>L2</u>	liver with 11	7	<u>L2</u>
<u>L1</u>	(reduc\$ or decreas\$ or alter\$ or modif\$) near6 tropism near5 adenovir\$	152	<u>L1</u>

END OF SEARCH HISTORY

Genera	te Collection	Print

Search Results - Record(s) 1 through 5 of 5 returned.

- ☑ 1. 20040142473. 20 Feb 04. 22 Jul 04. Means and methods for fibroblast-like or macrophage-like cell transduction. Vogels, Ronald, et al. 435/456; C12N015/861.
- 2. 20040043489. 22 Aug 03. 04 Mar 04. Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use. Havenga, Menzo, et al. 435/456; C12N015/861.
- 3. 20040033605. 20 Mar 03. 19 Feb 04. Gene delivery vectors provided with a tissue tropism for dendritic cells. Havenga, Menzo, et al. 435/456; 435/372 C12N015/861 C12N005/08.
- 4. <u>20040002060</u>. 24 Jan 03. 01 Jan 04. Fiber shaft modifications for efficient targeting. Kaleko, Michael, et al. 435/5; 435/235.1 435/320.1 435/325 435/456 435/69.3 530/350 536/23.72 C12Q001/70 C07H021/04 C12N007/00 C12N015/861 C07H021/02 C07K014/005.
- 5. <u>20030215948</u>. 27 Mar 03. 20 Nov 03. Fiber shaft modifications for efficient targeting. Kaleko, Michael, et al. 435/456; 435/235.1 435/320.1 435/370 C12N015/861 C12N007/00 C12N005/08.

Generate Collection

Print

Terms	Documents						
knob and L4	5						

Prev Page Next Page Go to Doc#

=> d his (FILE 'HOME' ENTERED AT 18:29:32 ON 23 AUG 2004) FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 18:29:43 ON 23 AUG 2004 208 S (REDUC? OR DECREAS? OR ALTER? OR MODIF?) (6A) TROPISM (5A) ADENOV L1 37 S LIVER AND L1 L26079 S ADENOVIR? (3A) (12 OR 16 OR 28 OR 40) L3 6 S L2 AND L3 L44 S KNOB AND L4 L5 1 DUP REM L5 (3 DUPLICATES REMOVED) L6 3 DUP REM L4 (3 DUPLICATES REMOVED) L7=> d bib ab 16 MEDLINE on STN DUPLICATE 1 1.6 ANSWER 1 OF 1 MEDLINE AN2003042985 PubMed ID: 12551989 DN Reduction of natural adenovirus tropism to TTthe liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. Nakamura Takafumi; Sato Kenzo; Hamada Hirofumi ΑU Department of Molecular Medicine, Sapporo Medical University, S1 W17, CS Chuo-ku, Sapporo 060-8556, Japan.. Nakamura.Takafumi@mayo.edu Journal of virology, (2003 Feb) 77 (4) 2512-21. SO Journal code: 0113724. ISSN: 0022-538X. CYUnited States Journal; Article; (JOURNAL ARTICLE) DTLAEnglish FS Priority Journals EM200303 Entered STN: 20030129 ED Last Updated on STN: 20030316 Entered Medline: 20030314 The initial recognition and binding of adenovirus vector to the host cell AΒ surface is mediated by interaction between the adenovirus fiber knob protein and its receptor, the coxsackievirus and adenovirus receptor (CAR). This natural tropism of adenovirus vector needs to be ablated in order to achieve targeted gene transfer. To this end, we noted that adenovirus serotype 40 (Ad40) contains two distinct long and short fibers; the short fiber is unable to recognize CAR, while the long fiber binds CAR. We generated adenovirus serotype 5-based mutants with chimeric Ad40-derived fibers, which were composed of either long or short shafts together with CAR binding or nonbinding The capacity of these adenovirus mutants for in vitro and in vivo gene transfer to liver cells was examined. In the case of primary human hepatocytes displaying a high expression level of CAR and alphav integrin, both CAR binding ability and fiber shaft length played important roles in efficient transduction. Most significantly, the high transduction efficiency observed in the liver and spleen following intravenous administration of adenovirus vector was dramatically reduced by both ablation of fiber-CAR interaction and the use of replaceable short fiber. In other tissues displaying a low level of transduction, no significant differences in transduction efficiency were observed among adenovirus vector mutants. Furthermore, incorporation of a 7-lysine-residue motif at the C-terminal end of CAR-nonbinding short fiber efficiently achieved transduction of target cells via the heparan-containing receptor. Our results demonstrated that the natural tropism of adenovirus in vivo is influenced not only by fiber-CAR

interaction but also by fiber shaft length. Furthermore, our strategy may be useful for retargeting adenovirus to particular tumors and tissue types

with specific receptors.

```
ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
Ь7
     Havenga Menzo, Jans Emco; Bout, Abraham; Vogels, Ronald
IN
     Adenoviral gene delivery vectors with cell type specificity for
TI
     mesenchymal stem cells and therapeutic uses
SO
     PCT Int. Appl., 63 pp.
     CODEN: PIXXD2
     PATENT NO.
                        KIND
                                DATE
                                          APPLICATION NO.
                                                                   DATE
                                           ______
                                                                   ------
                         A2
                                20030116
                                         WO 2002-NL443
                                                                   20020705
     WO 2003004661
PΙ
                                20031030
                         A3
     WO 2003004661
            AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
             FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK,
             SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW,
             AM, AZ, BY, KG
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
                                           EP 2001-202619
                                20030129
     EP 1279738
                          A1
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                           EP 2002-746193
     EP 1406666
                                20040414
                          A2
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     The present invention provides novel methods and means for delivering a
AΒ
     heterologous nucleic acid of interest to mesenchymal stem cells by
     providing recombinant adenoviral vectors provided with, or having a
     natural tropism for mesenchymal stem cells, typically in combination with
     a reduced tropism for other kinds of cells, in particular liver
     cells. The invention also provides mesenchymal stem cells provided with a
     heterologous nucleic acid through the use of a recombinant adenoviral
     vector according to the invention, and the use of such mesenchymal stem
     cells for the preparation of medicaments for the treatment of multiple
     sclerosis, rheumatoid arthritis, angiogenesis and bone related disorders,
     for instance in treatments that involve bone (re)generation.
                                                        DUPLICATE 1
     ANSWER 2 OF 3
                      MEDLINE on STN
L7
     Nakamura Takafumi; Sato Kenzo; Hamada Hirofumi
ΑU
     Reduction of natural adenovirus tropism to
TT
     the liver by both ablation of fiber-coxsackievirus and
     adenovirus receptor interaction and use of replaceable short fiber.
SO
     Journal of virology, (2003 Feb) 77 (4) 2512-21.
     Journal code: 0113724. ISSN: 0022-538X.
     The initial recognition and binding of adenovirus vector to the host cell
AB
     surface is mediated by interaction between the adenovirus fiber knob
     protein and its receptor, the coxsackievirus and adenovirus receptor
     (CAR). This natural tropism of adenovirus vector needs to be ablated in
     order to achieve targeted gene transfer. To this end, we noted that
     adenovirus serotype 40 (Ad40) contains two distinct long
     and short fibers; the short fiber is unable to recognize CAR, while the
     long fiber binds CAR. We generated adenovirus serotype 5-based mutants
     with chimeric Ad40-derived fibers, which were composed of either long or
     short shafts together with CAR binding or nonbinding knobs. The capacity
     of these adenovirus mutants for in vitro and in vivo gene transfer to
     liver cells was examined. In the case of primary human
     hepatocytes displaying a high expression level of CAR and alphav integrin,
```

both CAR binding ability and fiber shaft length played important roles in

efficient transduction. Most significantly, the high transduction efficiency observed in the **liver** and spleen following intravenous administration of adenovirus vector was dramatically reduced by both ablation of fiber-CAR interaction and the use of replaceable short fiber. In other tissues displaying a low level of transduction, no significant differences in transduction efficiency were observed among adenovirus vector mutants. Furthermore, incorporation of a 7-lysine-residue motif at the C-terminal end of CAR-nonbinding short fiber efficiently achieved transduction of target cells via the heparan-containing receptor. Our results demonstrated that the natural tropism of adenovirus in vivo is influenced not only by fiber-CAR interaction but also by fiber shaft length. Furthermore, our strategy may be useful for retargeting adenovirus to particular tumors and tissue types with specific receptors.

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

IN Vogels, Ronald; Schouten, Govert Johan; Bout, Abraham

TI Adenoviral vectors with low antigenicity for delivery of nucleic acids to synoviocytes for the gene therapy of rheumatoid arthritis

SO PCT Int. Appl., 131 pp.

		ODEN: PIXXD2 ATENT NO.				KIND DATE															
ΡI	 WO 200052186				A1 20000908			WO 2000-NL133													
1.1	***	W:		AE, AL,													CR,	CU,			
													GH,								
													LR,								
													RO,								
													UZ,								
			-						TJ,		,	,	,	,	•	•	•	•			
		PW.	GH,								TZ.	UG.	ZW.	AT,	BE,	CH,	CY,	DE,			
		1011.	חגר	ES.	FT.	FR.	GB.	GR.	TE.	TT.	LU.	MC.	ΝL,	PT.	SE,	BF,	ВJ,	CF,			
															•	ŕ		·			
	EP									MR, NE, SN, TD, TG EP 2000-908116				20000303							
			AT,																		
			-	-	LT,				,	•	•	Í	•	•	-						
	ďΡ	2002537816							1112		JP 2	000-	6027	96		2	0000	303			
	NZ 527290									NZ 2	000-	5272	90		2	0000	303				
		5276									NZ 2	000-	5276	34		2	0000	303			
	NZ 527635							0326		NZ 2	000-	5276	35		2	0000	303				
		1.2 32.333															1		~ ~		

The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect said nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analog thereof. Preferably said virus capsid is an adenovirus capsid. Preferably said adenovirus is a subgroup B adenovirus, preferably adenovirus 16.

Preferably said tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or

analog thereof. The invention further presents methods for the treatment of diseases, preferably joint related diseases.

AΒ